{
    "nct_id": "NCT05415709",
    "official_title": "Randomized Phase I Study Assessing the Safety and Tolerability Hyperthermic Intraperitoneal Chemotherapy (HIPEC) At Completion of Interval Cytoreductive Surgery Compared to Surgery and Chemotherapy Prior to Surgery for Patients with Stage III/IV Ovarian Cancer Undergoing Neoadjuvant Chemotherapy.",
    "inclusion_criteria": "* Ability to understand (English-speaking), and willingness to sign a written, informed consent\n* Age > 18 years old\n* Newly diagnosed stage III or IV epithelial (serous, mucinous, or endometrioid) ovarian, fallopian tube or peritoneal cancer diagnosed by:\n\n  * Biopsy/histology (either by interventional radiology or laparoscopy) OR\n  * Cytology; If diagnosis is based on cytology the following criteria must be met:\n\n    * Immunohistochemistry on the block from cytology to demonstrate Mullerian origin\n    * Presence of pelvic mass AND CA 125 > 200kU/I AND CA125/CEA ratio > 25 at initial diagnosis\n    * Omental cake or other metastases larger than 2 cm in the upper abdomen and/or regional lymph node metastasis irrespective of size (diagnosed by computed tomography [CT]/magnetic resonance imaging [MRI], ultrasound, or laparoscopy)\n* Patient planned for or currently receiving neoadjuvant chemotherapy due to the fact that optimal primary CRS was determined not to be feasible by the primary surgeon\n* Patient must be planned or scheduled to undergo interval cytoreductive surgery after cycle 3-4 of neoadjuvant surgery\n* Completion of three cycles of neoadjuvant chemotherapy (NACT) with standard therapy (carboplatin [area under the curve (AUC) 5-6] day [D]1 + paclitaxel [175 mg/m^2] D1 every 3 weeks)\n\n  * Following 3-4 cycles of NACT partial or complete response\n  * Following 3-4 cycles of NACT at least 50% decrease in CA-125 level between pre-cycle 1 and post-cycle 3/prior to surgery\n* Fit for major surgery, American Society of Anesthesiologists (ASA )1 or ASA 2\n* Eastern Cooperative Oncology Group (ECOG) performance-status score of 0-2\n* Serum creatinine < 1.4 mg/dL\n* Creatinine clearance > 60 ml/min (Cockcroft-Gault formula)\n* White blood cell count > 3.5 x 10^9 cells/L\n* Absolute neutrophil count > 1.5 kg/ul\n* Platelets > 100,000/ul\n* Total bilirubin within 1.5 x normal institutional limits\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal\n* For quality of life assessment, baseline questionnaires should be filled in before randomization\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of breast cancer or previous malignancy within 5 years prior to inclusion, with the exception of radically excised basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* Low grade serious carcinoma of the ovary or borderline ovarian tumors\n* History or current diagnosis of inflammatory bowel disease\n* History of allergic reactions to compounds of similar chemical or biologic composition to cisplatin, carboplatin, and paclitaxel\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia\n* Patients in whom an optimal or complete cytoreduction cannot be performed will be excluded at the time of surgery and be replaced",
    "miscellaneous_criteria": ""
}